Cupid Secures Rs. 16.23 Crore Orders For Male Condoms From Central Medical Services Society

Cupid Limited, a leading manufacturer, has garnered orders totalling Rs. 16.23 crores from the Central Medical Services Society (CMSS) for the supply of male condoms, the company informed in a press statement on Monday. Established as a Central Procurement Agency (CPA) with Cabinet approval, CMSS plays a crucial role in streamlining drug procurement and distribution for the Department of Health & Family Welfare (DoHFW), under the Ministry of Health and Family Welfare, Government of India.

Cupid successfully secured two separate orders for male condoms from CMSS, amounting to Rs. 9.65 crores and Rs. 6.58 crores, respectively. The company aims to fulfil these orders by April 2024, as disclosed in the exchange filing on January 8, 2024.

Aditya Halwasiya, Managing Director of Cupid , expressed excitement about this significant allocation from the Government of India, highlighting the company’s unwavering commitment to supporting the government’s vision of promoting a safe and healthy lifestyle for all citizens. He stated, “This collaboration underscores the importance of ensuring access to vital resources for the well-being of the community at large.”

Furthermore, Halwasiya emphasised Cupid Limited’s alignment with the Government of India’s initiative to “Help India Play Safe.” He mentioned that Cupid Limited’s proposed production capacity expansion in the next 18-24 months positions the company well for future orders from the government.

This development not only strengthens Cupid Limited’s partnership with the Government of India but also reflects the company’s dedication to contributing to public health initiatives. The successful execution of these orders is anticipated to play a vital role in advancing the accessibility of essential resources within the healthcare sector.

Related Posts

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care